Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Is the Forecast for the Acute Respiratory Distress Syndrome (ARDS) Market Growth in 2025?

The market for Acute Respiratory Distress Syndrome (ARDS) has experienced a swift expansion over the past few years. It is projected to escalate from $1.29 billion in 2024 to $1.42 billion in 2025, at a Compound Annual Growth Rate (CAGR) of 10.4%. Progress in critical care medicine, the aging demographic, lung rehabilitation, and interdisciplinary care teams have all contributed to this significant growth in the historic period.

What Is the Forecast for the Acute Respiratory Distress Syndrome (ARDS) Market Size Through 2029?

The market size for acute respiratory distress syndrome (ARDS) is anticipated to experience quick expansion in the upcoming years, reaching $2.17 billion in 2029 with a compound annual growth rate (CAGR) of 11.1%. Factors contributing to growth during the projected period include global readiness for healthcare crises, advancements in vaccines and the management of infectious diseases, the rise of telemedicine and remote patient monitoring, and the implementation of patient-centric care models. Key trends to watch for during this period are the emergence of artificial lung devices, customized ventilation strategies, protective ventilation methods for the lungs, and drug therapies tailored for various ARDS subclasses.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=13005&type=smp

What are the Key Market Players in Acute Respiratory Distress Syndrome (ARDS) Market and How They’re Evolving?

Major companies operating in the acute respiratory distress syndrome (ards) market are Johnson & Johnson Services Inc., Novartis AG, GlaxoSmithKline PLC, Medtronic PLC, Boehringer Ingelheim International GmbH, Gilead Sciences Inc., Amgen Inc., Fresenius SE & Co. KGaA, Koninklijke Philips N.V., Baxter International Inc., Teva Pharmaceutical Industries Ltd., CSL Behring, Terumo Corporation, ResMed Inc., Smiths Medical Inc., Dräger Safety AG & Co. KGaA., Getinge AB, Mallinckrodt PLC, Masimo Corporation, United Therapeutics Corporation, Fisher & Paykel Healthcare Corporation Limited, Hamilton Medical AG, Zuventus Healthcare Ltd., Windtree Therapeutics Inc., Faron Pharmaceuticals Oy, AcelRx Pharmaceuticals Inc.

What Are the Primary Growth Drivers in the Acute Respiratory Distress Syndrome (ARDS) Market?

The rise in pneumonia cases is predicted to fuel the expansion of the acute respiratory distress syndrome (ARDS) market. The infection known as pneumonia impacts either or both lungs, leading to the air sacs, or alveoli, being filled with fluid or pus. The resulting inflammation of the lungs escalates blood vessel permeability and causes fluid to leak into the alveoli. This fluid accumulation hampers the exchange of oxygen and carbon dioxide, resulting in respiratory discomfort. As reported by the Centre for Tropical Medicine and Global Health, a healthcare research organization based in the UK, as of November 2023, pneumonia cases in Kenya had significantly surged to 793,864 in 2022-2023, a leap from the 477,186 cases in 2020-2021. Consequently, the rising prevalence of pneumonia is driving the acute respiratory distress syndrome (ARDS) market’s growth.

Acute Respiratory Distress Syndrome (ARDS) Market Driver: The Expected Rise in Respiratory Diseases is Predicted to Propel the Acute Respiratory Distress Syndrome (ARDS) Market

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=13005&type=smp

What Are the Leading Segments in the Global Acute Respiratory Distress Syndrome (ARDS) Industry?

The acute respiratory distress syndrome (ARDS) market covered in this report is segmented –

1) By Type: Diagnosis, Treatment

2) By Cause: COVID-19 Disease 2019 (COVID-19), Sepsis, Inhalation Of Harmful Substances, Severe Pneumonia, Other Causes

3) By Severity: Mild, Moderate, Severe

4) By End User: Hospitals, Clinics, Ambulatory Service Centers, Other End Users

Subsegments:

1) By Diagnosis: Imaging Tests, Blood Tests, Lung Function Tests, Other Diagnostic Methods

2) By Treatment: Mechanical Ventilation, Medications, Extracorporeal Membrane Oxygenation (ECMO), Supportive Care, Other Treatment Options

What Are the Key Market Trends in the Acute Respiratory Distress Syndrome (ARDS) Industry?

Leading firms in the acute respiratory distress syndrome (ARDS) sector are concentrating their efforts on creating innovative medicines and supplements, such as Aviptadil, HSP90 inhibitors, among others, to maintain their market status. Aviptadil, a synthetic version of the vasoactive intestinal peptide (VIP), specifically targets receptors on type II alveolar cells of the lungs. For instance, in November 2022, Zuventus Healthcare Ltd., a major pharmaceutical manufacturer based in India, introduced Aviptadil as a treatment for acute respiratory distress syndrome. This vasoactive intestinal peptide supplement improves breathing and reduces mortality rates in ARDS patients by safeguarding and regenerating Type-2 Pneumocytes, rejuvenating Type-1 Pneumocytes, boosting surfactant production, and inhibiting IL-6 (interleukin 6) and tumor necrosis factor (TNF)-alpha.

Access The Full Report Here:

https://www.thebusinessresearchcompany.com/report/acute-respiratory-distress-syndrome-ards-global-market-report

What Is the Regional Outlook for the Acute Respiratory Distress Syndrome (ARDS) Market?

North America was the largest region in the acute respiratory distress syndrome (ARDS) market in 2024. The regions covered in acute respiratory distress syndrome (ARDS) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Purchase The Full Report Today:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=13005

This Report Delivers Insight On:

1. How big is the acute respiratory distress syndrome (ards) market, and how is it changing globally?

2. Who are the major companies in the acute respiratory distress syndrome (ards) market, and how are they performing?

3. What are the key opportunities and risks in the acute respiratory distress syndrome (ards) market right now?

4. Which products or customer segments are growing the most in the acute respiratory distress syndrome (ards) market?

5. What factors are helping or slowing down the growth of the acute respiratory distress syndrome (ards) market?

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 2071930708

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model